Kura Oncology Announces Commencement of Public Offering of Common Stock

Kura Oncology (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock.

As quoted in the press release:

In connection with the offering, Kura Oncology expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering.  There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The securities described above are being offered by Kura Oncology pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed by Kura Oncology with the Securities and Exchange Commission (the “SEC”) and that was declared effective on December 4, 2017.  A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC’s website located at https://www.sec.gov.

Click here to read the full press release.